Pre-Conference Workshop Day

Tuesday | September 12, 2023


08:30 – 11:30 am
Workshop A

Quantifying Structural & Functional Differences Between Healthy & Diseased Mitochondria with High Resolution Imaging


Discover the latest imaging techniques to improve our fundamental understanding of mitochondrial biology and function to accelerate drug development.

Workshop highlights include:

  • Cutting edge toolkit to process cryo-electron tomography data for high resolution and three-dimensional analysis of mitochondria
  • Unlocking a new era of structural and functional insights
  • Mapping mitochondria structure across scales

12:00 – 3:00 pm
Workshop B

Developing & Validating Preclinical Disease Models for Chronic Diseases

  • Karel Erion Director of Preclinical Research, Capacity Bio
  • Andy Lee Co-founder, Chief Financial Officer & Chief Technology Officer, Vincere Biosciences


After many strategies for treating neurodegenerative and cardiometabolic diseases have seen little success, the role of mitochondrial dysfunction is moving to the forefront.

Workshop highlights include:

  • Understand the most recent research into mitochondrial dysfunction in aging
  • Explore the latest cell engineering techniques
  • Discover how to improve the translational efficacy of early disease models and improve target-identification and validation

Advancing Preclinical Modelling of Inherited & Rare Mitochondrial Diseases

  • Marni Falk Executive Director of Mitochondrial Medicine Frontier Program, Children's Hospital of Philadelphia
  • Sherine Chan Chief Executive Officer & Co-Founder, Neuroene Therapeutics


To date, animal mitochondrial DNA has remained resistant to transfection and has limited the availability of models for rare diseases.

Workshop highlights include:

  • Discover the key hurdles towards developing truly predictive models to improve translation and drug efficacy in humans
  • Explore the newest mitochondrial transfer strategies for developing animal models to recapitulate system-wide energy crisis of mitochondria
  • Understand how this can be applied to the drug development pipeline and predicting efficacy and safe therapeutic windows

3:30 – 6:30 pm
Workshop C

Decision Making Behind Preclinical Mitochondrial Toxicity Studies


Mitochondrial toxicity is a major concern of many drugs development projects across disease areas, therapeutic strategies, and drug development.

Workshop highlights include:

  • Understand the science-lead decision making across multiple drug development projects
  • Explore the key technologies, tools, and processes to comprehensively demonstrate drug safety early to promote translation